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Abstract
In 2013, illegal drug use was responsible for 1.8% of years of life lost in the
European Union, alcohol was responsible for 8.2% and tobacco for 18.2%,
imposing economic burdens in excess of 2.5% of GDP. No single European
country has optimal governance structures for reducing the harm done by
nicotine, illegal drugs and alcohol, and existing ones are poorly designed,
fragmented, and sometimes cause harm. Reporting the main science and
policy conclusions of a transdisciplinary five-year analysis of the place of
addictions in Europe, researchers from 67 scientific institutions addressed
these problems by reframing an understanding of addictions.  A new paradigm
needs to account for evolutionary evidence which suggests that humans are
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needs to account for evolutionary evidence which suggests that humans are
biologically predisposed to seek out drugs, and that, today, individuals face
availability of high drug doses, consequently increasing the risk of harm.  New
definitions need to acknowledge that the defining element of addictive drugs is
‘heavy use over time’, a concept that could replace the diagnostic artefact
captured by the clinical term ‘substance use disorder’, thus opening the door for
new substances to be considered such as sugar. Tools of quantitative risk
assessment that recognize drugs as toxins could be further deployed to assess
regulatory approaches to reducing harm. Re-designed governance of drugs
requires embedding policy within a comprehensive societal well-being frame
that encompasses a range of domains of well-being, including quality of life,
material living conditions and sustainability over time; such a frame adds
arguments to the inappropriateness of policies that criminalize individuals for
using drugs and that continue to categorize certain drugs as illegal. A health
footprint, modelled on the carbon footprint, and using quantitative measures
such as years of life lost due to death or disability, could serve as the
accountability tool that apportions responsibility for who and what causes
drug-related harm.
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Introduction
A consortium of 67 scientific institutions from 24 European coun-
tries and beyond, covering over thirty scientific disciplines rang-
ing from anthropology to toxicology, responded to an invitation 
by the European Commission to study the place of addictions in 
contemporary European society. The resulting five-year endeavour, 
the Addictions and Lifestyles in Contemporary Europe - Reframing 
Addictions Project (ALICE RAP, www.alicerap.eu), went beyond 
this. It reframed our understanding of addictions and formulated a 
blueprint for re-designing the governance of addictions. This paper 
summarizes the project’s conclusions, pointing to new understand-
ings of the science and policy of nicotine, illegal drugs and alcohol, 
hereafter collectively referred to as ‘drugs’1–6. Although this paper 
does not cover process addictions (e.g., gambling3), much of what 
is said applies to addictions beyond drugs.
The paper starts by discussing why we need to re-think addictions. 
It contrasts two powerful pieces of evidence: the harm done by 
drugs, versus the poorly structured existing governance approaches 
designed to manage such harm. The paper continues by consider-
ing three bases for re-thinking the addiction concept in ways that 
could lead to improved strategies across different jurisdictions: rec-
ognition that there is a biological predisposition for people to seek 
out and ingest drugs; that heavy use over time becomes a replace-
ment concept and descriptor for the term substance use disorder; 
and that quantitative risk assessment can be used to standardize 
harm across different drugs, based on drug potency and expo-
sure. The paper finishes by proposing two approaches that could 
strengthen addictions governance: embedding governance within a 
well-being frame, and adopting an accountability system—a health 
footprint that apportions responsibility for who and what causes 
drug-related harm.
Why do we need to re-think addictions?
The need to re-think addictions is exemplified by the extent of 
harm caused by the drugs themselves, and by the fact that no single 
country, at least in Europe, has fully overcome poorly managed and 
fragmented governance structures.
Harm done by drugs
A standard way to document and describe the interference that 
drugs have on human biology and functioning is to use years of 
life lost to premature mortality (YLL) and disability adjusted life 
years (DALYs). DALYs are a measure of health that sum up YLL 
and years or life lost due to disability and detriments in functioning 
(YLD). In 2013, illegal drug use was responsible for 1.8% of YLL 
in the European Union (EU), alcohol was responsible for 8.2% and 
tobacco for 18.2% (Table 1), imposing economic burdens in excess 
of 2.5% of GDP7.
The data in Table 1 represents harm to the drug user. However, drug 
use also harms the health of others. For instance, operating machin-
ery under the impact of illegal drugs can cause injury to others8,9. 
Although decreasing globally, second-hand smoking was estimated 
to kill more than 330 thousand people worldwide in 2013, and 
caused about 7% of the burden of disease in DALYs attributable to 
tobacco smoking10. The extent of harm to others caused by alcohol 
consumption is estimated to be proportionally even larger, mainly 
due to traffic accidents, violence, including homicide, and foetal 
alcohol spectrum disorders11.
Dataset 1. Source data underlying the results presented in Table 1
http://dx.doi.org/10.5256/f1000research.10860.d154573
The data was based on the IHME Global burden of diseases, 
injuries and risk factors study (http://www.healthdata.org/gbd).
Fragmented governance structures
Governance is defined as the processes and structures of public 
policy decision making and management that engage people across 
the boundaries of public agencies, levels of government, and public, 
private and civic spheres to carry out a public purpose that cannot be 
Table 1. Burden of disease caused by drug exposure in the European Union (EU) in 2013. 
Source: own calculations based on IHME Global burden of diseases, injuries and risk factors study 
(http://www.healthdata.org/gbd).
Risk factor Sex YLLs in 1,000
YLLs per 
100,000
% of all 
YLLs
DALYs 
in 1,000
DALYs per 
100,000
% of all 
DALYs
Illegal drug use Men 1,069.8 428.5 2.5% 1,749.2 700.7 2.3%
Women 292.7 111.9 0.9% 580.5 222.0 0.8%
Total 1,362.5 266.6 1.8% 2,329.7 455.8 1.6%
Alcohol use Men 4,558.7 1,826.1 10.4% 5,981.4 2,396.0 7.9%
Women 1,584.0 605.8 5.1% 2,019.8 772.5 2.9%
Total 6,142.8 1,201.9 8.2% 8,001.2 1,565.5 5.5%
Tobacco use Men 10,036.4 4,020.3 23.0% 11,280.0 4,518.5 14.9%
Women 3,552.2 1,358.6 11.5% 4,405.0 1,684.7 6.4%
Total 13,588.6 2,658.6 18.2% 15,685.0 3,068.8 10.9%
YLL: Years of life lost due to premature mortality
DALYs: Disability adjusted life years
Source data available in Dataset 1102.
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accomplished by any one sector alone12. The involvement of mul-
tiple stakeholders in governance is not without risk. The exclusive 
use of top-down bureaucratic approaches cannot maximize societal 
benefits when dealing with ‘wicked problems’ that are highly resist-
ant to resolution13 (for definition of wicked problems, see ‘The New 
Governance of Addictive Substances and Behaviours by Anderson 
et al6). An analysis of 28 European countries found that no sin-
gle country had a comprehensive policy for all drugs (including 
nicotine, illegal drugs and alcohol) within a broad societal well-
being approach. For more detail, see ‘Governance of Addictions: 
European Public Policies’, by Albareda A et al1.
There are at least three reasons for ineffective and poorly inte-
grated governance. Firstly, the same harm done by drugs is defined 
and understood in different ways in different countries and state 
systems14–16. Seen from a trans-national comparative perspective, 
there is a lack of a common understanding of appropriate poli-
cies, and responses are often constrained by approaches that are 
tied to assumptions that are not evidence-based4. Ways of thinking 
about the harm done by drugs vary enormously, with considerable 
heterogeneity between different drugs, and between international, 
national and local levels of governance. For detail, see ‘Concepts 
of Addictive Substances and Behaviours across Time and Place, by 
Hellman et al4.
Secondly, a multitude of commercial, political and public stake-
holders are active in addictions governance on national and 
international levels. In any given society, stakeholders that have 
power, means and influence are likely to achieve an advantageous 
influential position. The concepts of addiction are also shaped 
by popular constructs promulgated by the mass media and cus-
toms in the general population. Stakeholder positions and percep-
tions of drug problems also vary over time and by area4, implying 
that sustainable approaches must be interwoven into societal and 
governance structures.
Thirdly, corporate power17, through multiple channels of influence, 
can hinder evidence-based policy decisions5. Corporate strategies 
often include attempts to influence civil society, science and the 
media, as part of a wider aim to manage and, if possible, capture 
institutions that set policy. Transparency is insufficient given that 
the multiplicity of channels with corporate power is poorly 
acknowledged and understood by policy makers. Therefore, the 
rules in place to ensure level playing fields for discussions and 
equitable decision-making across all factors are inadequate6.
Reframing addictions
The consensus reached under ALICE RAP was that there are at 
least three ways to reframe addictions that could lead to improved 
strategies across different jurisdictions. These include: 
1)  Recognition that humans have a biological predisposition for 
seeking out and ingesting drugs;
2)  Recognition that ‘heavy use over time’ should replace the con-
cept and term ‘substance use disorder’;
3)  Recognition that a quantitative risk assessment accounting for 
drug potency and drug exposure, can standardize measures of harm 
across different drugs.
Evolutionary evidence for biological predisposition
The idea that human exposure to drugs did not occur until late in 
human evolution—thus leaving our species inexperienced—is often 
posited as one of the reasons that these substances cause so much 
harm18. However, multidisciplinary scientific evidence suggests 
otherwise. Many substances consumed today are not evolutionary 
novelties18,19. In the story of terrestrial life over the last 400 mil-
lion years or so, one ongoing theme has been the “battle” between 
plants and the animals that eat them. Of the many defence mecha-
nisms in existence, plants produce numerous chemicals, including 
tetrahydrocannabinol, cocaine, nicotine, and opiates, all of which 
are potent neurotoxins that deter consumption of plant tissue by 
animals18. From an evolutionary perspective, we thus find natu-
ral selection for compounds that discourage consumption of the 
plant via punishment of potential consumers. By contrast, there 
has been no natural selection for expression of psychoactive 
compounds which encourage consumption (i.e., via consumer 
reward), which has also been predicted by neurobiological and 
behavioural psychology theories of reward and reinforcement for 
contemporary drugs20.
Counterbalancing the development of plant neurotoxins, plant- 
eating animals have evolved to counter-exploit plants’ pro-
duction of drugs, for instance by exploiting the anti-parasitic 
properties of some of them18. Many species of invertebrates and 
vertebrates engage in pharmacophagy, the deliberate consumption 
and sequestration of plant toxins, to dissuade parasites and preda-
tors. In a human context, present day examples of pharmacophagy 
may be seen with Congo basin hunter gatherers, amongst whom the 
quantity of cannabis21 and nicotine22 consumed is titrated against 
intestinal worm burden - the higher the intake, the lower the worm 
burden. In individuals treated with the anti-worm drug abendazole, 
the number of nicotine-containing cigarettes smoked is reduced22.
Although parasite-host co-evolution is recognized as a potent selec-
tive force in nature, other, subtler evolutionary dynamics may affect 
human and animal interactions with plant-based drugs, including 
that they may buffer against nutritional and energetic constraints on 
signalling in the central nervous system23. Ethnographic research 
reveals that many indigenous groups classify “drugs” as food, 
rather than psychoactive entities, and that they are perceived as 
having food-like effects, most notably for increasing tolerance 
for fatigue, hunger and thermal stress in nutritionally-constrained 
environments23. The causes of these perceived effects have not 
been a research question, but there are clues that the “food” clas-
sification may be literal rather than allegorical. Common plant 
toxins not only mimic mammalian neurotransmitters, they are also 
synthesized from the same nutritionally-constrained amino acid 
precursors, such as tyrosine and tryptophan. In harsh environ-
ments, toxic plants could function as a “famine food” providing 
essential dietary building blocks, or, may function as a direct 
substitute for nutritionally-constrained endogenous neurotrans-
mitters. There is some evidence to support this hypothesis in 
animal research; for example, wood rats in cold environments 
reduce thermoregulatory costs by modulating body temperature 
with plant toxins consumed from the juniper plant24.
In the case of ethanol, its presence within ripe fruit suggests 
low-level but chronic dietary exposure for all fruit-eating animals, 
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with volatilized alcohols potentially serving in olfactory localiza-
tion of nutritional resources (i.e., animals can use the smell of alco-
hol to locate food over long distances)19. Molecular evolutionary 
studies indicate that an oral digestive enzyme capable of rapidly 
metabolizing ethanol was modified in human ancestors near the 
time that they began extensively using the forest floor, about 10 
million years ago25; humans have retained the fast-acting enzyme to 
this day. By contrast, the same alcohol dehydrogenase in our more 
ancient and mostly tree-dwelling ancestors did not oxidize etha-
nol as efficiently. This evolutionary switch suggests that exposure 
to dietary sources of ethanol became more common as hominids 
adapted to bipedal life on the ground. Ripe fruits accumulating on 
the forest floor could provide substantially more ethanol cues and 
result in greater caloric gain relative to fruits ripening within the 
forest canopy, and our contemporary patterns of alcohol consump-
tion and excessive use may accordingly reflect millions of years of 
natural dietary exposure19.
This evolutionary evidence does not imply that humans also evolved 
to specifically consume nicotine, for example, or that nicotine use is 
beneficial in the modern world. What is novel in the modern world 
is the high degree of availability, and high concentration of psy-
choactive agents and routes of consumption that promote intoxica-
tion. What is different with alcohol in the modern world is novel 
availability through fermentative technology, enabling humans to 
consume it as a beverage, devoid of food bulk, with higher ethanol 
content, and artificially higher salience than that which character-
izes fruit fermenting in the wild. The evolutionary evidence has two 
implications: firstly, policies that prohibit the use of drugs are likely 
to fail because people have a biological predisposition to seek out 
chemicals with varying nutritional and pharmacological properties; 
and secondly, in present-day society, drug delivery systems have 
been developed that are beyond what is reflected in the natural envi-
ronment, particularly with respect to levels of potency, availability 
and taste, which could be argued as being the more central driv-
ers of harm. Potency is largely determined by producer organisa-
tions operating in markets, which, from the perspective of overall 
societal well-being, are inadequately managed26. Better regulation 
of potency can become a major opportunity for additional policy 
interventions - for example with alcohol, see ‘Evidence of reducing 
ethanol content in beverages to reduce harmful use of alcohol’ by 
Rehm et al.27.
Heavy use over time
To better understand the interference of drugs in human biology 
and functioning, the consensus reached in ALICE RAP was that the 
concept and term ‘heavy use over time’ should be proposed as the 
replacement for ‘substance use disorder’. In medical settings and 
indeed often in academic and lay settings, heavy users of drugs are 
commonly dichotomized into those with a ‘substance use disorder’ 
or not. ‘Substance use disorder’ is a clinical construct that is often 
used as a shorthand to identify individuals who might benefit from 
advice or treatment. But as a condition in itself, it is a medical arte-
fact which occurs in all grades of severity, with no natural distinc-
tion between ‘health’ and ‘disease’28,29.
This is illustrated with alcohol. The associated chronic organ dam-
age (e.g., liver cirrhosis, cancers) exponentially increases in risk as 
alcohol consumption accumulates over time30,31. Unmanaged heavy 
drinking is associated with subsequent heavy drinking, often culmi-
nating in brain damage32, itself a consequence of heavy drinking33,34 
but also a driver of future behaviour.
Alcohol consumption itself is close to log-normally distributed in 
drinking populations, skewed towards heavy drinking35. There is 
no natural cut-off point above which “alcohol use disorder” defini-
tively exists and below which it does not. “Alcohol use disorder” is 
clinically defined as a score on a checklist of symptoms, and there 
is a smooth line exponential relationship between levels of alco-
hol consumption and the score on the checklist29,36. Heavy drink-
ing is a cause of the items on the checklist, including compulsion 
to drink more, which can also be a consequence of brain damage, 
itself caused by heavy drinking. Thus, “alcohol use disorder” is a 
diagnostic artefact. No more is needed to consider what is called 
“alcohol use disorder” other than heavy use over time28,29.
For alcohol (and other drugs as well), this approach does not imply 
that heavy use over time is the only cause of harm. There are other 
factors involved that that drive heavy alcohol use and harm3 that 
are independent of, or in interaction with, molecular and cellular 
levels (e.g., alcohol dehydrogenase polymorphisms37), individual 
levels (e.g., income38 and personality39) and environmental levels 
(e.g., stigma)
There is an ongoing discussion as to whether or not sugar is an 
‘addictive’ substance that should be captured in the same category 
as drugs26. Framing the problem as one of heavy use over time 
provides insight into this debate. As with alcohol and high blood 
pressure40, chronic disease risk associated with plasma glu-
cose levels has a continuous exponential relationship with sugar 
consumption41. The distribution of blood glucose levels is close 
to log-normally distributed in populations and skewed towards 
high consumption levels42. There is no natural cut-off point above 
which diabetes (or any other disease manifestation) linked to sugar 
definitively exists and below which it does not. Similar to the alco-
hol model where heavy use of alcohol over time leads to further 
heavy use of alcohol from the resulting brain damage, heavy use of 
sugar over time damages hippocampal function43, which leads to 
further heavy use of sugar over time44. Thus, in the ‘heavy use over 
time’ frame, sugar can be placed in the same category as alcohol 
and other drugs, and managed with similar governance approaches 
that promote public health.
Quantitative risk assessment
A core way to document the interference of drugs in human biol-
ogy and functioning is to use quantitative risk assessment (QRA). 
QRA is a method applied in regulatory toxicology, for example, to 
evaluate water contaminants, and before safety approvals for food 
additives or pesticides. QRA has not been widely applied to drugs. 
Previous approaches for ranking harm have mostly been based on 
expert judgements45,46 which have been criticized as being arbitrary 
and biased47.
The advantage of QRA is that it provides a formal scientific method 
to rank the harm-potential of drugs, making optimum use of avail-
able data48. There are several approaches for QRA available, with 
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Margin of Exposure (MOE) suggested by WHO49 as being most 
suitable for prioritizing risk management. In the alcohol field, MOE 
has been applied to evaluate the liver cirrhosis risk of ethanol, which 
is the single most important chronic disease condition attributable 
to alcohol globally50. MOE results have replicated those behind 
existing guidelines for low-risk drinking51. In a detailed study of the 
components in alcoholic beverages, ethanol was confirmed as the 
compound with highest risk52. In a detailed comparison between 
ethanol and non-metabolically produced acetaldehyde contained 
in beverages, it was also judged that the risk of ethanol comprises 
more than 99% of the total risk53. It can be concluded that the risk 
of alcoholic beverages can be evaluated by looking at the effects 
of ethanol alone. The situation is less clear for tobacco, for which 
some industry MOE studies find toxicants other than nicotine54,55. 
An MOE analysis of electronic cigarette liquids indicated that nico-
tine is the compound posing the highest risk56.
MOEs are calculated as the ratio of a toxic dose of the drug (usu-
ally the benchmark dose BMDL10, the lowest dose which is 95% 
certain to cause no more than a 10% negative outcome incidence) 
with the dose consumed either individually or on a population 
scale47. The higher the MOE, the lower the level of risk, with low 
risk not implying safety. An MOE of 100 means that the drug is 
being consumed at one hundredth of the benchmark dose; an MOE 
of 1 means that the drug is being consumed at this toxic dose. The 
MOE for drugs can be calculated taking into account a range of 
hazard outcomes in health and other well-being domains, as long as 
suitable dose-response data are available (which is not the case for 
most drugs and many well-being indicators). Therefore, analyses 
to date are primarily restricted to lethal outcomes based on animal 
studies. Results for European adults are summarized in Figure 1. 
The low MOE for alcohol (and thus high risk) is due to the high 
levels of consumption by European adults. The MOE results are 
consistent with the consensus of expert rankings in which cannabis 
is ranked with lower risk and alcohol with higher risk than current 
policies assume45,46. The MOE is inherent to the drug itself; it does 
not account for the harms that arise from drug delivery systems, 
for example, smoked tobacco, or from secondary effects such as 
unclean syringes used for heroin intake.
Of course, MOE, as presented here, focuses on the physical body 
of the adult user as the locus of harm. It does not take into account 
the sex and age of the user, or harm to individuals other than the 
user or at collective levels, which are a primary source of social dif-
ferentiation between drugs. It also focuses on mortality, rather than 
intoxication in the moment. Differences between the intoxicating 
power of substances in the moment, and in the behavioural con-
sequences of taking them, are primary reasons why, for example, 
societies have treated alcohol differently to tobacco. Nevertheless, 
we believe that MOE should be applied at the current stage even 
when the underlying toxicological data are incomplete, to provide 
a better alignment of prioritization of policy to the drugs associated 
with higher risks, which in this case are nicotine, cocaine, heroin 
and alcohol.
Towards better governance
We have described three harmonizing approaches to reframe our 
understanding of addictions: biological predisposition to seek out 
psychoactive substances; heavy use over time as a fruitful charac-
terisation; and quantitative risk assessment. Here, we propose two 
Figure 1. Margin of exposure for daily drug use estimated using probabilistic analysis. Source: Lachenmeier & Rehm (2015)47.
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Figure 2. Well-being framework, reproduced with permission from the OECD Better Life Index initiative. Source: OECD. (2011), How’s 
Life?: Measuring Well-being, OECD Publishing, Paris. DOI: http://dx.doi.org/10.1787/9789264121164-en57.
underlying pillars for a re-design of the governance of drug con-
trols: embedding drugs governance within a comprehensive model 
of societal well-being; and creating a health footprint which, mod-
elled on the carbon footprint, promotes accountability by identify-
ing who causes what harm to whom from drugs.
Societal well-being
We propose that societal well-being should be our overarching 
frame for a more integrated governance and monitoring of drug 
control policies. Societal well-being, as captured by OECD57, 
includes quality of life (health, education and skills, social connec-
tions, civic engagement, and personal security), material conditions 
(income, employment and housing) and sustainability over time 
(see Figure 2). Gross domestic product (GDP) is included as a sep-
arate domain, recognizing that, while economic well-being is an 
important component of societal well-being, GDP has significant 
limitations. GDP excludes, for example, non-market household 
activity such as parenting, and activities such as conservation of 
natural resources. GDP also includes activities which do not con-
tribute to well-being, such as pollution and crime, termed regret-
tables that are depicted within GDP but outside well-being. The use 
of and harm done by drugs are affected by and affect all well-being 
dimensions58.
Well-being analyses have found that, whilst some illegal drug poli-
cies may reduce health harms, they often come with adverse side 
effects including criminalization, social stigma and social exclusion, 
all of which exacerbate health harms59. Humans are hard-wired to be 
social animals60, with social networks strongly influencing tobacco 
use61 and alcohol intake62. Punitive drug policies bring about the 
opposite: social exclusion due to stigma and social isolation63–65. 
Engagement with illegal drugs conveys especially strong social 
meanings and can lead to stigma of marginalized heavy users, as 
opposed to the supposedly more responsible mainstream users66. 
This can lead to punitive societal responses. Meanwhile, exclusion 
from the mainstream may allow harms to continue unchecked. If a 
user is caught using drugs in a country with “zero tolerance” to ille-
gal drugs, the ensuing criminal sanctions will impede civic engage-
ment and any improvements in quality of life and material living 
conditions. For more detail, see ‘Well-being as a frame for under-
standing addictive substances’ by Stoll & Anderson58. Changes in 
life expectancy in Mexico illustrate the negative consequences of 
criminalization67. After six decades of gains in life expectancy in 
Mexico, the trend stagnated after 2000 for both men and women, 
and for men was reversed after 200568. This was largely due to an 
unprecedented rise in homicide rates, mostly as a result of drug 
policies promoting ‘gang wars’ and conflicts between gangs, the 
police and army69.
A well-being frame calls for whole-of-society approaches that pro-
gressively legalize illegal drugs to reduce violence and personal 
insecurity, while focusing on substances as drivers of harm6,70. It 
balances the complex factors impacting drug use and related harm 
through the continuous monitoring of policy effects in a proactive 
way, with regulations embedded in international coordination. It 
calls for whole-of-society approaches that avoid criminalization 
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where possible and where costs of addressing the problem are 
equally distributed across society. Governance strategies manage 
nicotine, illegal drugs and alcohol as a whole to avoid overlaps, 
contradictions, gaps and inequalities1. The concern should be 
focused on harms, both to the user and to others, including family 
and friends, communities and society as a whole. The structures 
to support the strategies should be coordinated and multi-sectoral, 
involving high-level coordination of health, social welfare, and jus-
tice agencies in the context of international treaties, and, impor-
tantly, equitable across the lifespan, between genders and cultural 
groups. To increase the pace of policy change, regional and local 
public policies can create policy communities and networks within 
a common international framework.
Managing ‘wicked problems’ requires clear rules of private sector 
engagement in policy making, particularly when private interests 
go against societal well-being6. An evolved governance system 
must include measures to avoid industry co-optation, through trans-
parency, checks and balances. Private sector stakeholders should 
operate within established rules.
Accountability
The ongoing monitoring of outcomes within a well-being framework 
would promote accountability. Modelled on the carbon footprint, we 
propose a health footprint as the accountability tool. Footprints were 
developed in the ecological field as a measure of human demand on 
ecosystems71, including water footprints72 and carbon footprints that 
apportion greenhouse gas emissions to certain activities, products 
and populations73. The central reason for estimating a carbon foot-
print is to help reduce the risk of climate change through enabling 
targeted and effective reductions in greenhouse gas emissions74.
The health footprint can be considered a measure of the total 
amount of risk factor attributable disability adjusted life years 
(DALYs)75 of a defined population, sector or action within a spatial 
(e.g., jurisdiction) or temporal boundary (e.g. one year). It can be 
calculated using standard risk factor-related YLL and DALY meth-
odologies of the Global Burden of Disease Study10 and of the World 
Health Organization75. Health footprints are a starting point. To 
be accountable, we ultimately need to understand what drives the 
health footprint (Figure 3).
Structural drivers
Above the health footprint of Figure 3 are the structural driv-
ers of harm that directly influence the size of the health footprint. 
Biological attributes and functions include, for example, the bio-
logical pre-disposition to seek out and use drugs. Genetic vari-
ants, for example, could be those that affect the function of alcohol 
dehydrogenase, influencing consumption levels and harm8,76. 
Changes in global population size and structure can increase 
absolute numbers of drug-related DALYs, even though rates per 
person can decrease over the same time7. As sociodemographic 
status improves in lower income countries, so do drug-related 
DALYs10; yet, for the same amount of drug use, people with lower 
incomes suffer more drug-related DALYs than people with higher 
incomes77.
Figure 3. Drivers of harm done by drugs and addictive behaviour.
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Circumstantial drivers
Above the structural drivers are the circumstantial drivers, those 
that can change. Related to drug potency and exposure, an MOE 
target for all drugs no greater than 10 has been argued6. Policies 
could achieve such a result by either reducing drug exposure or 
by reducing the potency of the drug. Technological developments 
have led to electronic nicotine delivery systems (widely known as 
e-cigarettes) as widespread alternatives to smoked tobacco, with 
current best estimates showing e-cigarettes to be considerably less 
harmful to health than smoked cigarettes78–80. It may be that once 
e-cigarettes are heavily produced and marketed by the tobacco 
industry, that society will see cigarette-like levels of sustained 
heavy use of nicotine. However, e-cigarette’s harm quotient 
should stay low, provided they are properly regulated in terms 
of their components, including nicotine. Social influences and 
attitudes drive harm through stigma, social exclusion and social 
marginalization; these are often side-effects of drug policies, which 
can bring more harm than drug use itself81,82.
Policies and measures
Policies that reduce exposure to drugs are essentially those that 
limit availability by increasing the price and reducing physical 
availability59,83,84. The absence of such evidence-based policies is 
an important driver of harm. Limits to availability bring a range of 
co-benefits to educational achievement and productivity, for exam-
ple, but they can also bring adverse effects – for example, the well- 
documented violence, corruption and loss of public income 
associated with some existing ‘illegal’ drug policies58,85. Individual 
choices and behaviour that drive harm from drug use are determined 
by the environment in which those choices and behaviours operate86. 
Banning commercial communications, increasing price and 
reducing availability are all incentives that impact individual behav-
iour. Research and development can be promoted to reduce the 
potency of existing drugs87 and their drug delivery packages27,56,78.
Unfortunately, there remain enormous gaps between the supply 
and demand of evidence-based prevention, advice and treatment 
programmes88–92. Called for by United Nations Sustainable Devel-
opment Goal 3.593, their supply can bring many co-benefits to soci-
ety, including reduced social costs and increased productivity94. The 
harm driven by the gaps is due in large part to insufficient resources 
and insufficient implementation of effective evidence-based pre-
vention and treatment programmes95. Currently these programmes 
represents less than 1% of all costs incurred to society by drugs96. 
Similar to medicines agencies (such as the European Medicines 
Agency) that assess and approve drugs, prevention agencies could 
be created95. Compounding the gap between supply and demand is 
the fact that often, considerable marginalization and stigmatization 
happens in the path to treatment, and this is then further exacer-
bated by the treatment itself82. The use of pharmacotherapy as an 
adjunct may be further limited due to ideological stances, poorly 
implemented guidelines, lack of appropriate medication, and even a 
perceived lack of effect, if the drug is available97.
The private sector is a core driver of harm, through commercial 
communications which include all actions undertaken by produc-
ers of drugs to persuade consumers to buy and consume more98. 
There are international models encouraging better control of 
commercial communications in the public health interest, the most 
notable being the Framework Convention on Tobacco Control83. In 
addition to commercial communications, the private sector drives 
harm through shaping drug policies, leading to more drug-related 
deaths5. Governance structures thus need to have the capability and 
expertise to supervise industry movements that shape drug-related 
legislation and regulations, including regulating and restricting 
political lobbying. One of the difficulties here is that politically 
driven change in difficult areas, such as drug policies, is highly 
dependent on collective decisions99 and influenced by what has 
been termed specular interaction100, in which a politician’s actions 
may be less determined by their own conviction, and more by their 
evaluation of beliefs of their rivals and friends.
The health footprint is the accountability system for who and what 
causes drug-related harm. Jurisdictional entities can be ranked 
according to their overall health footprint, in order to identify the 
countries that contribute most to drug attributable ill-health and pre-
mature death, and where the most health gain could be achieved 
at country level. Jurisdictional footprints could include ‘policy 
attributable health footprints’ which estimate the health footprint 
between current policy and ideal health policy. This would address 
the question: ‘what would be the improvement in the health foot-
print compared to present policies, were the country to implement 
strengthened or new policies?’ Conversely, the health footprint can 
provide accountability for when such evidence-based policy is not 
implemented correctly.
A range of sectors are involved in nicotine and alcohol related risk 
factors. These include producer and retail organizations such as 
large supermarket chains, and service provider companies such as 
advertising and marketing industries. There is considerable overlap 
between sectors, and estimates will need to determine appropri-
ate boundaries for health footprint calculations. Companies could 
report their health footprints and choose to commit to reducing them 
by a specified amount over a five to ten-year time frame. Direct 
examples of producer action could include switching from higher to 
lower alcohol concentration products27, and switching from smoked 
tobacco cigarettes to e-cigarettes80.
Conclusions
The points stated above underscore the need to redesign the gov-
ernance of drugs; in Europe, and globally. Margins of exposure 
estimates for four drugs (nicotine, cocaine, heroin and alcohol) are 
exceedingly high and thus call for determined action. Drugs are 
responsible for a high proportion of years of life lost in the Euro-
pean Union; tobacco accounted for 18.2% of life years lost, illegal 
drugs for 1.8%, and alcohol for 8.2% in 2013. There are many side 
effects of existing policies, such as stigma, social exclusion, lack of 
personal security, civil unrest and homicide58.
Under the auspices of ALICE RAP, a large, multidisciplinary 
team of addiction scientists put forward a range of arguments for 
moving progressively towards regulated legalization of certain 
illegal drugs, proposing a well-being frame that calls for whole-
of-society approaches and continuously monitors and accounts 
for adverse side effects of drug policy. Humans have a biological 
pre-disposition to seek out a range of drugs, so prohibitionist 
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policies are likely to run into difficulty - and they have. Legaliza-
tion does not imply that drug governance is left to market forces 
alone - the experience of nicotine and alcohol demonstrates that this 
is not possible. Instead, drug governance requires comprehensive 
regulation, with adequate and transparent rules of the game for 
stakeholder involvement, and appropriate international regulatory 
frameworks. With a health footprint, it can be documented who 
causes what harm from nicotine, illegal drugs and alcohol in the 
public and private sectors. Public bodies and private companies 
should be required to publish their health footprints on an annual 
basis, and indicate their plans for reducing the health footprint.
The consensus that ALICE RAP reached will not come without 
push-back. Without input from evolutionary theory, neurobiol-
ogy will continue to maintain that human drug use is initiated 
and sustained by reward and reinforcement at both biological and 
behavioural levels, compounded by mistaken views that the human 
encounter with drugs is a relatively new evolutionary experience, 
and human vulnerability to drugs in moral, behavioural, and bio-
logical dimensions. Disease classification systems are based not 
only on measurement, but on qualification, and thus payment, for 
treatment. The concept heavy use over time does not prevent the use 
of qualification definitions for treatments. Threshold consumption 
levels determining treatment can be defined as levels above which 
advice and treatment have been shown to reduce the development 
or progression of end-organ damage. Extending margin of exposure 
analyses for a range of outcomes beyond mortality will overcome 
concern of one metric for drug policy - its strength is that it allows 
standard comparison across drugs and indicates options for chang-
ing both dose and exposure.
Whilst measuring societal well-being as a whole has gained 
support, the implications for drug policy that favour regulated 
legalization will meet resistance from those who favour prohibi-
tion, particularly as prohibition is based more on a moral than an 
evidence-based standpoint, as has been the case with alcohol101. 
The footprint implies responsibility, which is often difficult for 
both public and private sectors to accept, in particular for producer 
companies whose vested interests might be challenged.
What we propose in this paper are large adjustments to our under-
standing of addictions and to what needs to be done to effectively 
reduce the widespread harms done by drugs. We hope that what 
we have written might start a process for better drug policy for the 
good of the public.
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The opinion article on reframing and rethinking the science and policy of nicotine, illegal drugs and
alcohol is an interesting article that challenges some of the current ‘frames’ to analyze addictive
substances and the governance of these substances. The surplus value of the article lies in the insights
provided from a truly interdisciplinary approach, including disciplines beyond the ‘usual suspects’ of
health economics, criminology and psychology. It will stimulate discussing on governance approaches
that promote public health.
Overall, this is a well-written article addressing the important topic of reframing the science and policy of
nicotine, illegal drugs and alcohol. The main messages of the paper are clearly described and sufficiently
accentuated.
 
There is one important opinion that is included in the article that should be substantiated more extensively
though. On p. 7 (final paragraph) and again in the overall conclusion, the authors plea to ‘legalize’ (p. 7)
illegal drugs and they plea for approaches ‘that avoid criminalization’; in the conclusion, gain they plea for
a ‘regulated legalization’ (p. 9), and for a ‘legalization (p. 10). First, the concepts used are not
synonymous, as they are different legal concepts with a different meaning/ with different implications.
Avoiding criminalization is not the same thing as legalization (avoiding criminalization does not require
legalization, but can be reached through depenalization or by making use of the expediency principle on
the prosecution level to settle drug offences); neither is ‘regulated legalization’ and ‘legalization’ (neither
alcohol nor tobacco are legalized for that matter). I would advise the authors to reconsider the terms used
and to extend on the implications of the option they suggest. Second, and linked to this, the transition
from the paragraph on the consequences of criminalization (in Mexico) and the plea for legalization on p.
7 is too abrupt.  
Next, there are some minor questions that arise at some paragraphs in the article we would like the
authors to elaborate on.
On page 3, section ‘Harm done by drugs’, the authors refer to the use of DALYs as a standard way to
quantify the harm caused by drugs. The authors propose to use DALYs as a measure for the health
footprint. I agree with this since the use of DALYs enables to make comparisons associated with the
burden of drugs across substances and/or countries possible. It is well known that the (mis)use of drugs
result in an increased risk of a number of conditions (somatic diseases, mental disorders, injuries).
Relative risks (together with prevalence data) can serve as input to estimate substance-attributable
1 2
1
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 Relative risks (together with prevalence data) can serve as input to estimate substance-attributable
fractions (SAFs) which can be used to quantify the economic burden of  drug (mis)use. So, please
elaborate a bit on this in the section ‘Harm done by drugs’.
On p. 5, the authors state that the heavy use over time of sugar can be placed in the same category as
alcohol and other drugs. Do the authors imply that heavy use over time of sugar should be governed to
the same extent as, e.g., the heavy use of heroin (and that heavy use should be the main element in
policy decisions)? Or do the authors plea for a differentiated  substance policy between different types of
substances? Does this mean that the focus should be on rewarding healthy lifestyle behavior? In addition,
policy initiatives to reduce the use of sugar should be integrated together with other lifestyle-related
interventions such as the promotion of more physical activity, healthy eating (not restricted to only
reducing the use of sugar). Please, add some comments on this.
On p. 6, the authors state that suitable dose-response data have to be available and they continue to
state ‘which is not the case for most drugs and many well-being indicators’. Could the authors add what
the main reasons are why these data are missing and how this lack of data could be overcome?
On p. 6, the authors only briefly touch upon the intoxicating power of substances in the moment and upon
the behavioral consequences of taking them. One might argue that taking one of these elements is
suitable for prioritizing risk management as well? Could the authors thus more clearly argue why, they
suggest to use MOE and not, e.g. intoxicating power?
On page 9 section ‘Policies and measures’, ‘Banning commercial communications’, ‘increasing price’, and
‘reducing availability’ are incentives that impact individual behavior. Generally, these incentives could be
considered as more or less ‘restrictive incentives’ that impact individual behavior. On the other hand,
incentives can also be considered as ‘rewards’. What do the authors think about e.g. the use of financial
incentives to reward ‘healthy behavior’? How could/should these be incorporated into an integrated
governance approach?
Some of the concepts in figure 3 are not explicitly discussed in the article, or at least not in a
logical/sequential order (e.g. regulating private sector and research and development are, resource
allocation and incentivizing individual behavioral are not). Could the authors briefly discuss each of the
elements in this interesting figure? Could the authors please elaborate a bit more on the advantages
(added value) and limitations of the conceptual model?
 No competing interests were disclosed.Competing Interests:
We have read this submission. We believe that we have an appropriate level of expertise to
confirm that it is of an acceptable scientific standard.
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The present manuscript by Anderson . "Reframing the science and policy of nicotine, illegal drugs et al
and alcohol...." is a well-written succinct, compilation of the findings and suggestions obtained from the
Addictions and Lifestyle in Contemporary Europe--Reframing Addictions Project (ALICE-RAP).  The
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 Addictions and Lifestyle in Contemporary Europe--Reframing Addictions Project (ALICE-RAP).  The
authors, and colleagues of associated publications, astutely highlight the need for a systematic lexicon for
addiction science and policy.  This lexicon is needed not only internationally but also intranationally at all
levels of the private and public sector.  Thus, the need to destigmatize addiction and recognize that it is a
natural phenomenon requiring treatment, and not criminalization, in some individuals.  This will require a
"reframing of addiction" in order to facilitate the treatment of addiction.  While progress has been made in
recognizing that addiction is a medical condition, that progress has not been matched by efforts to
destigmatize addiction.  As long as addiction is not recognized as a natural phenomenon that isn't isolated
to one substance, but includes multiple licit and illicit substances (and possibly behaviors/process
addictions), the public and policy makers will continue to have a mind set that addiction represents a
"wicked problem".  Thus, addiction will continue to be criminalized with most funds targeting addiction
policy being slated towards the criminal justice system rather than social and clinical medicine to treat the
phenomenon.  The authors put forth a hypothesis that the lack of consistent addiction policy not only
internationally but also intranationally is the absence of a standardized measure of social, medical,
economic, and civic damage resulting from addiction to different licit and illicit substances.  Disability
Adjusted Life Years (DALYs) is a recommended way to address the health impact disparity observed
across different classes of substance with abuse potential.  DALYs can be used to determine Margin of
Exposure (MOE) as a Quantitative Risk Assessment (QRA), which can be standardized across
"substances of abuse".  When this is done, as seen in Figure 1, it is clear that the licit substances ethanol
and nicotine have a significantly greater deleterious "health footprint" compared to most illicit drugs.  Yet,
global addiction policy is not consistent in recognizing, nor addressing, this disparity.  Finally the authors
recognize and remind the reader that addiction policy is influenced by social, political and market place
suppositions that are not evidence-based.  Moreover, with the nontransparency of lobbying activity by
multiple, and diverse, stakeholders on policy makers will resist a "reframing of addiction" in order for there
to be consistent, equitable and humane policy both internationally and intranationally. 
As far as particular manuscript content goes, the authors discuss the relatively novel concept that plant
neurotoxins, which many drugs of abuse mimic or contain, are evolutionarily conserved in the plant
kingdom.  Thus, these toxins dissuade animals from ingesting the plant.  Contrarily, plant chemicals that
promote ingestion, in and of themselves, through reinforcing and/or rewarding effects are evolutionarily
"weeded out".  This point is receiving greater support through the recognition that immune signaling,
centrally and peripherally, plays an important role in the neurobiology of addiction.
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